21
Harbour BioMed
2142.HK·HKEXSuzhou CNFounded 2016800 employees
Small CapbiotechPublicOncologyImmunology
Platform: Batoclimab FcRn
Market Cap
$0.5B
All Drugs
2
Clinical Trials
3
Failed / Terminated
0
FDA Approved
0
Stock Price & Catalysts (2142.HK)
Loading 2142.HK stock data...
Drug Pipeline (2 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Motaratamab | 214-4407 | Phase 2/3 | 1 | MDM2 | MCLFL | ||
| Kemarelsin | 214-300 | NDA/BLA | 2 | WEE1 | ALS |
SEC Filings & Financial Documents
SEC filings are not available for HKEX-listed companies.
Harbour BioMed trades on HKEX (CN). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (2)